Results 91 to 100 of about 45,592 (164)

A comparison by mismatch repair status of real‐world characteristics and outcomes in patients with stage II/III rectal cancer in the Netherlands

International Journal of Cancer, Volume 158, Issue 4, Page 963-976, 15 February 2026.
What's new? Mismatch repair deficiency (dMMR) in rectal cancer is rare, and knowledge about tumor biological behavior, response to treatment, and clinical outcomes in this subset of patients is limited. This nationwide cohort study including 182 patients with dMMR rectal cancer found that they were younger and had more poorly differentiated tumors ...
Renee A. Lunenberg, Ingrid A. Franken, Frederieke H. van der Baan, Femke P. C. Sijtsma, Geraldine R. Vink, Manon N. G. J. A. Braat, Leon M. G. Moons, Miangela M. Lacle, Marloes A. G. Elferink, Susan Boklage, Martijn P. W. Intven, Jamie Garside, Miriam Koopman, Rob van Wuijtswinkel, Jeanine M. L. Roodhart   +14 more
wiley   +1 more source

Autoregulation of the MET receptor tyrosine kinase by its intracellular juxtamembrane domain. [PDF]

Biochem J
Linossi EM, Espinoza CA, Estevam GO, Fraser JS, Jura N.   +4 more
europepmc   +1 more source

Spatial evidence for carcinoma in situ (CIS) as an entity in human papillomavirus (HPV)‐associated tonsillar squamous cell carcinoma (TSCC)

International Journal of Cancer, Volume 158, Issue 4, Page 1080-1092, 15 February 2026.
What's new? Human papillomavirus (HPV)‐associated tonsillar squamous cell carcinoma (TSCC) is suspected of originating from tonsillar crypts, where HPV can persist in latent form. Detection is further complicated by the possible absence of premalignant stages, namely carcinoma in situ (CIS). Here, the authors investigated tumor origin in HPV‐associated
Tobias Näsman, Madeleine Birgersson, Linda Marklund, Anders Näsman   +3 more
wiley   +1 more source

Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions. [PDF]

Cancers (Basel)
Winter M, Jeroch J, Wetz M, Rauschendorf MA, Wild PJ.   +4 more
europepmc   +1 more source

Plasma proteomic profiling and molecular clustering reveal immune‐defined prognostic subtypes in lung adenocarcinoma

International Journal of Cancer, Volume 158, Issue 4, Page 858-865, 15 February 2026.
What's new? Lung adenocarcinoma shows considerable heterogeneity in disease progression and therapeutic response. Here, the authors analyzed tumor samples through proteomic profiling and applied network‐based clustering. They identified two distinct patient groups with different demographic, clinical, and molecular characteristics.
Ujjwal Neogi, Anoop T. Ambikan, Kati Turkowski, Marc A. Schneider, Vanessa M. Beutgen, Johannes Graumann, Hauke Winter, Marek Bartkuhn, Werner Seeger, Soni S. Pullamsetti, Rajkumar Savai   +10 more
wiley   +1 more source

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. [PDF]

Cells
Garg V, Hofmann RNHM, Saleem M, Mirzaiebadizi A, Hashemi GS, Hameed T, Jooyeh B, Pudewell S, Mehrabipour M, Mosaddeghzadeh N, Piekorz RP, Ahmadian MR.   +11 more
europepmc   +1 more source

Overexpression of CDT1 inhibits cell cycle progression at S phase by interacting with the mini‐chromosome maintenance complex and causes DNA damage

FEBS Open Bio, Volume 16, Issue 2, Page 352-364, February 2026.
CDT1 is an essential protein for DNA replication licensing that loads the MCM complex, the eukaryotic replicative DNA helicase, onto replication origins. Overexpression of CDT1 induces cell cycle arrest at the S phase. Here we showed CDT1 inhibits the progression of replication forks by interacting with the MCM complex, leading to the stalling and ...
Takashi Tsuyama, Nonoka Takayama, Rina Tanaka, Yuuki Arai, Yohko Yamaguchi, Yuko Nawata, Yutaro Azuma, Shusuke Tada   +7 more
wiley   +1 more source

3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth. [PDF]

PLoS One
Nam AY, Joo SH, Lee NY, Yoon G, Park JW, Na M, Shim JH.   +6 more
europepmc   +1 more source

The HRAS Variant c.175G>A (p.Ala59Thr) Causes a Predominantly Ectodermal Phenotype Lacking Classic Costello Syndrome Features

American Journal of Medical Genetics Part A, Volume 200, Issue 2, Page 407-418, February 2026.
ABSTRACT Costello syndrome (CS) is a rare dominant HRAS RASopathy characterized by curly hair, cardiac abnormalities, craniofacial anomalies, and developmental delay. HRAS codon 58, 59, and 60 variants are associated with milder phenotypes. We describe a three‐generation family with a previously unreported heterozygous HRAS variant c.175G>A (p.Ala59Thr)
Nikole Rautiainen, Eveliina Brandt, Kaisa Kettunen, Outi Elomaa, Sirpa Kivirikko, Leila Jeskanen, Katriina Lappalainen, Nelli Sjöblom, Juha Kere, Katariina Hannula‐Jouppi, Liisa Harjama   +10 more
wiley   +1 more source

Molecular Alterations and Pathways in Intrahepatic Cholangiocarcinoma: Available Evidence and New Perspectives. [PDF]

Int J Mol Sci
Astore M, Fabbri L, Monte A, Deiana C, Rizzo A, Tavolari S, Deserti M, Brandi G, Palloni A, Frega G.   +9 more
europepmc   +1 more source